Methods to limit pathogenic mitochondrial DNA amplification in mitochondrial replacement therapy

Case ID:
Web Published:

Technology Overview

Maternally inherited mitochondrial DNA (mtDNA) mutations, estimated to affect 778 newborns in US each year, result in mitochondrial dysfunction and may cause severe and life threatening disease with no effective treatment, such as Leigh Syndrome, MELAS or NARP. Therefore, mitochondrial replacement techniques have been developed to prevent pathogenic mtDNA transmission from mothers to their children. Although the estimated mtDNA carryover is less than 1-2 %, the potential of the postnatal bottleneck amplification remains a concern for in vitro fertilization following spindle transfer.


Researchers at Oregon Health & Science University developed a method to match donor and recipient mtDNA haplotypes to avoid preferential mutant mtDNA replication therefore limiting the probability of disease transmission.     



Mitalipov, S. et al. Mitochondrial replacement in human oocytes carrying pathogenic mitochondrial DNA mutations. Nature, 540, 270-275 (2016).


Licensing Opportunity

Technology 2352 is available for licensing and/or collaborative development.


If interested in learning more, please contact Technology Transfer and Business Development at and reference Tech Id No. 2352.


Patent Information:
For Information, Contact:
Michele Gunness
Senior Technology Development Manager
Oregon Health & Science University
(503) 494-8200
Dmitry Temiakov
Shoukhrat Mitalipov
Biological Materials
Biological Materials - Cell Lines
Therapeutics - Reproductive
© 2020. All Rights Reserved. Powered by Inteum